News and Comments

Exelixis: Important Collaborative Agreements with Roche and Bristol-Myers Squibb

  Monday, February 27, 2017

Exelixis (EXEL) announced a new collaboration with Roche on a phase 1b dose escalation study of a combination of Exelixis cabozantinib in combination with Roche’s anti-PD-L1 immuno-therapy drug atezolizumab. The study aims at evaluating the safety and tolerability  of the combination in patients with locally advanced or metastatic solid tumors. Enrollment is scheduled to begin mid-year 2017; Exelixis will sponsor the trial, and Roche will provide atezolizumab.  More...

Companies Targeted for Takeover Yet Can Thrive on their Own

  Thursday, February 02, 2017

It seems that the global Takeda (TKPYY) has guessed well what it should pick in order to bring the most effective targeted treatments to cancer patients allover the globe. Cancer management has unreservedly changed. What seems now to have become the best treatment choices are those that would accommodate the new wave of extremely promising immunotherapy approaches.     More...

Exelixis: Results Demonstrate the Potential of Cabozantinib to Become the Gold Standard First Line Treatment for Advanced RCC

  Monday, May 23, 2016

Yes, indeed, the good news has come from the randomized CABOSUN phase 2 trial with Exelixis’ (EXEL) drug cabozantinib. The news is indirectly telling us that Cabozantinib may soon become the first-line treatment for previously untreated advanced renal cell carcinoma (RCC).  More...

The FDA Approval of Exelixis Drug Cabometyx™ Is Indeed Great News

  Tuesday, April 26, 2016

Congratulation.   More...

One Year Accomplishments Vs. One Cent Missed in Agenus Financial Report

  Thursday, March 03, 2016

Agenus (AGEN) is a project in the making since the firm has decided to play an integral part in immuno-oncology, doing everything possible towards building checkpoint modulator antibodies, in addition to its protective and therapeutic vaccines.    More...

Exelixis: Great News Towards Great Changes

  Tuesday, March 01, 2016

Exelixis’ (EXEL) quarterly results beat analysts’ expectations, which was the least of our concerns. The details of the firm’s actions during the past year, however, confirmed our conviction that the recently approved products will be taken care of responsibly by the firm that created them and believed in them against all pessimistic opinions.  More...

Exelixis Will Begin Reaping the Fruits

  Tuesday, November 10, 2015

 More...

The Stream of Exelixis Good News is Real

  Thursday, October 22, 2015


 More...

Why Switzerland Approval of Exelixis and Roche Drug Combination for melanoma is a Big Deal?

  Thursday, August 27, 2015

 More...

EXELEXIS: The Importance Of The Public Offering. XOMA: What Should We Do Now?

  Thursday, July 23, 2015

Why the financing through a secondary public offering was a must for Exelixis?  More...


Recent Postings


Archive


Tags

Biogen Idec (BIIB) Merck (MRK) Regeneron (REGN) Spike Therapeutics (ONCE) Roche (RHHBY) Multiple Myeloma Ridaforolimus PORTOLA (PTLA) Rapamune Agenus (AGEN) C4 Therapeutics Sanofi (SNA) IDERA (IDRA) HALOZYME (HALO) Agenus (AGEN Tysabri MODERNA Global Cell Therapeutics (GBT) Intrexon (XON) Advaxis (ADXS) Genentech Valeant Pharmaceuticals International (VRX) Bellicum (BLCM) GUARDIAN HEALTH KERYX (KERX) Theravance Bio Pharma (TBPH) JUNO (JUNO) OSI (OSIP) Sequenom (SQNM) Ziofpharm (ZIOP) Velcade (bortezomib) Abbott Laboratories (ABT) CEMPRA (CEMP) ARGOS (ARGS) Prolor Biotech (PBTH) KITE (KITE) Alder Biopharmaceuticals (ALDR) Auspex (ASPX) Mirati Therapeutics (MRTX) LEXICON (LXRX) Onyx (ONXX) Elan (ELN) Pluristem (PSTI) NANTKWEST (NK) NOVOCURE (NVCR) Revlimid (lenolidamide) OncoCyte (OCX) Vertex (VRTX) Sangamo (SGMO) Adaptimmune (ADAP) Trastuzumab-DM1 ImmunoGen (IMGN) GlaxoSmithKline (GSK) Vitae Pharmaceuticals (VTAE) PTC Therapeutics (PTCT) TOKAI (TKAOI) ADVENTRIX (ANX) Dendreon (DNDN) galapagos (GLPG) Aimmune Therapeutics (AIMT) Amgen (AMGN) Incyte (INCY) Idenix (IDIX) Anacor (ANAC) Dynavax (DVAX) Ocular Therapeutix (OCUL) ISIS (ISIS) Sanofi (SNY) Illumina (ILMN) Human Longevity (HLI) AstraZeneca (AZN) RenenxBio (RGNX) CRISPR Therapeutics (CRSP) Inovio (INO) Telaprevir SERES THERAPEUTICS (MCRB) Benlysta (belimumab) ARCA (ABIO) Anadys (ANDS) Bristol-Myers Squibb (BMY) Jazz Pharmaceuticals (JAZZ) Seattle Genetics (SGEN) ACADIA (ACAD) Ariad (ARIA) Endometrial Cancer Theravance (THRX) SYNTA (SNTA) ZALTRAP™ NEKTAR (NKTR)) Sarepta (SRPT) INNOVIVA (INVA) Intercept (ICPT) Sanofi-Aventis (SAN) VANDA (VNDA) Array Pharmaceuticals (ARRY) SUNESIS PHARMACEUTICALS (SNSS) Xoma (XOMA) Prosensa (RNA) JOUNCE THERAPEUTICS (JNCE) Alnylam (ALNY) Human Genome Sciences (HGSI) AERIE PHARMACEUTICALS Ionis (IONS) Micromet (MITI) Intermune (ITMN) BIOMARIN (BMRN) CompuGen (CGEN) REGULUS (RGLS) Biocryst (BCRX) Gilead (GILD) Roche (ROCHE) Galena (GALE) Zerenex Editas (EDIT) Exelixis (EXEL) Herceptin ABBVIE (ABBV) AGOS (ARGS) Cytokinetics (CYTK)